MCRB Seres Therapeutics Inc

$MCRB $XBI $IBB 🤠🐂 KENDER CAME BACK FOR ONE MORE RODEO! 35 years at Merck. A key role in the Schering-Plough acquisition. Over 100 business development and licensing transactions throughout his career. This man knows how deals get done. Seres has cash runway through at least Q1 2027 and is engaging potential partners, including companies with ICI franchises. SER-155, the irEC opportunity, and the broader pipeline give strategic players something to evaluate. AND LOOK AT THIS CHART. Brutally oversold. RSI crushed. After all this relentless selling, sentiment is in the gutter while the science and strategic opportunities remain. How much more bearish can the market get before the pendulum swings the other way?👀 You really think Kender came back to Seres to ride off into the sunset with MCRB sitting at these valuations? I don't think he wants this to be his legacy. I think he wants one more BIG WIN! If there's a deal to be made, I want THIS GUY at the table! ONE MORE RODEO, RICHARD🤠

$MCRB $XBI $IBB A LITTLE SHAREHOLDER INITIATIVE. I’ve spent the entire morning reaching out to nearly every investment firm / institutional investor I could find that has previously owned MCRB. I sent them a simple message: MCRB is back at extreme valuation levels. Take another look. These are firms that have already done the work on Seres before. They know the company. They know the science. They’ve owned the stock. If even one or two whales decide to put MCRB back on their radar, that could make a dramatic difference in a stock this small. I’m not pretending my emails are going to single-handedly move the market. But sitting around waiting for someone else to notice isn’t going to help either. So I’m doing my part. And if anyone here wants to use the same letter, screenshot attached. Feel free. Send it to funds. Send it to analysts. Send it to anyone who might actually take a fresh look at MCRB. We don’t need every institution to come back. We just need one or more to start paying attention.

$MCRB $XBI $IBB ~$25M market cap? The disconnect between price and potential value is staggering. ✅ No debt ✅ Trading below Cash ✅ Cash runway through at least Q1 2027 ✅ Breakthrough Therapy + Fast Track designations ✅ Strong SER-155 data ✅ Expansion into irEC, with management engaging potential partners, including companies with ICI franchises ✅ Management evaluating financing options alongside SER-155's next steps, suggesting multiple potential paths forward ✅ Directors chose stock options instead of annual cash compensation, further aligning themselves with shareholders 📉 Brutally oversold technicals. Extreme selling pressure, depressed sentiment, and a valuation that gives the pipeline ZERO CREDIT. I continue to believe a partnership or potentially even an acquisition is a very real possibility in the coming weeks/months. Looking forward to getting some answers from the Q3 ER/Business Updates in early November! Patiently waiting and ACCUMULATING💰

$MCRB Every day management delays shareholder saving action, it dims chances of shareholder getting anything significant. This is quickly becoming abadoned ship and vultures are circling. Look today XBI is up 3.65% and this turd is down 3.72%. It is simply pathetic that it cant go up on strong biotech days like today. It is very unlikely that someone will pay 400%-500% premium to acquire assets. We are not living in those times anymore. How is this management not recognizing sense of urgency is mind boggling. Having no communication with shareholders is irresponsible. Doesn't matter if you are from Merck with 30 years etc. Time is essence. If you cant get a deal done in time - you lost the opportunity, permanently.

$MCRB 🐂🚀 **TAKE SOME OF THOSE PROFITS AND PUT THEM TO WORK IN MCRB.** Seres Therapeutics is incredibly oversold, with RSI under 20 and the stock trading near all-time lows. Quite frankly, I think this is **one of the most compelling risk/reward opportunities in small-cap biotech right now.** 🔥 **SER-428 DATA PRESENTATION THIS THURSDAY, OCT. 22, AT IDWEEK!** 🧬 SER-155. irEC. Allo-HSCT. Multiple pipeline programs. Potential partnerships. Strategic possibilities. The stock has been crushed, sentiment is awful, and this setup looks increasingly primed for a **MASSIVE BOUNCE** if buying pressure or meaningful news arrives. 👀 I believe October and early November could bring important developments. Sitting on profits in $MRNA , $IBRX , $IOVA , $RAPP or elsewhere? **Consider taking a little off the table and looking at MCRB.** You can thank me later. 😂🐂

$MCRB It honestly boggles my mind that Seres is currently valued at just $28M despite Flagship and Nestle collectively owning roughly a quarter of the company and having such strong strategic/pharma connections. The amount of time management has spent pursuing partnerships and the quality of the SER-155 data and Phase 2 ready platform, it’s hard to understand why a meaningful partnership hasn’t materialized yet.

$MCRB i bought into loads of shitty companies but this has to be the biggest piece of shit I've ever invested in

$MCRB … So preclinical data for Ser-428 & Ser-603, as well as clinical trial data for Ser-155/allo-HSCT and Ser-155/ICI irEC are so horrific and meaningless that the company deserves a ‘wallstreet valuation’ of $10M below current cash on hand?? 🤔🧐 hmmm

$MCRB ‘’DON’T FORGET’’ Seres today looks far more positioned for a strategic transaction than to grow independently. It has sold VOWST, eliminated debt and significantly reduced costs, workforce and real estate commitments, while monetizing the remaining Nestlé milestones. Meanwhile, SER-155 has Breakthrough Therapy + Fast Track designations, is Phase 2-ready but paused while Seres seeks funding/partners, and has shown promising irEC data. They also put Richard Kender, a former Merck executive with extensive BD/licensing experience, in charge while actively seeking partners. With a market cap of only a few tens of millions, if Big Pharma values SER-155 at $150–300M, it could potentially make more sense to acquire the entire company rather than license the asset and pay upfront fees, milestones and royalties. A buyout is far from guaranteed, but Seres is now much leaner, cleaner and easier to acquire. Very interesting setup.

$MCRB $XBI $XLV I follow several other companies beyond Seres such as $IREN & $CIFR , and this is EXACTLY the kind of thinking that can make you money in beaten-down small caps. Market valuations don't always reflect the intrinsic value of a company's assets or its long-term potential. Sometimes companies trade at a fraction of what their underlying assets could be worth to the right strategic buyer. SENTIMENT IS YOUR BEST FRIEND WHEN IT COMES TO BUYING UNDERVALUED ASSETS. You make money by recognizing the disconnect between market price and underlying value BEFORE the rest of the market catches on. That's a big part of why I'm so interested in $MCRB. I believe the market is assigning virtually no value to Seres' pipeline and strategic potential. I continue to believe a partnership or potentially even an acquisition is a very real possibility in the coming weeks🚀 Depressed share price ≠ lack of value. Sometimes the biggest opportunities are hiding in plain sight💰 HAPPY HALLOWEEN BULLS!

$MCRB — IOVA PROFITS → MORE MCRB! 🐂💰 Scored some NICE long-trade dip buys on $IOVA this morning, and guess where those profits are going? RIGHT BACK INTO $MCRB! 🎯📈 The Fed held rates steady, markets are looking GOOD, and I'm especially loving the strength in $XBI and $XLV. 🔥 Meanwhile, $MCRB is sitting at a valuation I still believe massively undervalues its pipeline and strategic potential. Cash runway through at least March 2027, SER-155, irEC, SER-428, SER-603, SER-147 and disclosed partner engagement. TAKE PROFITS. RECYCLE CAPITAL. ACCUMULATE CONVICTION. 🐂🚀 Every successful dip trade is another opportunity to add to the position I'm most excited about. The loading zone won't last forever… Sub $2 is a gift horse staring at you👀 I continue to believe a partnership or potentially even an acquisition is a very real possibility in the coming weeks.🚀 Looking forward to the Q3 ER/Business Updates in early November! Patiently waiting and ACCUMULATING💰

$MCRB one hypothesis to the current share price is , its been blatantly brought down so they negotiate without threatening to use atm. even though, i would think board memebers are more than eager to have this company sold. who knows . microbiome is the future. seres has incurred a 1 billion dollar loss since inception. anyone who wants to get to where they are would do the same. 300 million for the company use to sound very realistic

$MCRB the only thing shareholders have cling to is the fact short interest is close to multi year lows. someone must be expecting some good news down here. the slience sure is deafening. anybody have anything decent to add?

$MCRB feeling pretty good about this decision. I keep thinking a buyout is imminent but this keeps tanking.

$MCRB IOVA releasing non small cell lung cancer results tomorrow morning. It’s trending number 1 right now. Gonna fly tomorrow!

$MCRB I owned $250K worth of shares of this terrible company. Oh my freaking god. This company is nothing without the money of nestle.

$MCRB at what point does nestle pull the trigger on seres? this company is bare bones, no debt, VERY promising pipeline with a serious unmet need, valued at “give or take“ COH. SI is still at 4-5 year low,(down 50+%) which leads me to belive the share price is just artificially brought down. we need a 300% move just to het back to $10. seems pretty hard for me to belive they are looking for funding while continuing to load up on options while zero growth has been given to the stock. that seems more like a buyout move but SP obviously doesnt suggest that. hmmm, just my hard earned money thinking over the weekend

$MCRB until when money - that’s the big question!🤔 I am not going to gamble. This company dissapointed me too often.

$MCRB I’ve added more shares to my long MCRB position; I think the time has come to start the climb back up to $20.

$MCRB is trading at roughly $0.14 pre-split. Let that sink in. Years of shareholder value destruction, massive dilution, and a reverse split. Meanwhile, executives continue collecting substantial compensation. At what point does management take accountability for this performance? What is the actual plan to create shareholder value?